Cystic Fibrosis Foundation issued the following clinical trial alerts in April
April 13, 2021
Status: Completed with results
Description: This study evaluated the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy (PERT). MS1819 is a non-porcine (not pig-derived) lipase-only enzyme for people with CF who have exocrine pancreatic insufficiency (EPI).
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 30% or greater
Number of Visits: 10
Length of Participation: 11 weeks
ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT03746483
April 14, 2021
Status: Enrolling
Description: This study will collect everyday observations that individuals with CF, who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®), make in their daily lives over 12 months. Participants will use the Folia app to track their routine treatments, medication usage, and symptoms, and will answer validated patient-reported outcome questionnaires. Participants who are participating in the CF Patient Registry will have their Registry data linked to their Folia tracking data to assess the relationship between any medication changes and changes in lung function. This study will not provide or make any treatment recommendations, and there are no required study visits.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 0
Length of Participation: 12 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04798014